DNDN (9.91) is -83% from its 2010 high. This must be close to a record drop in such a short period for a biotech company that did not encounter a clinical or regulatory setback during the period in question.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”